Bariatric surgery denied? We cite ASMBS, IFSO, and the trial data they ignored.

Why bariatric denials are different from any other surgical denial

Bariatric surgery is the only procedure category in which insurers routinely deny operations that are guideline-endorsed, FDA-approved, and demonstrably more durable than the medical alternatives. The reason is not clinical — it is structural. Bariatric surgery costs $20,000 to $40,000 up front and saves the insurer money over five to ten years. In a market where members switch plans every two to three years, the insurer paying for the surgery often is not the one capturing the savings. That misalignment is what created the 1991 NIH Consensus thresholds, the "supervised six-month diet program," the "investigational" labels for newer procedures, and the explicit plan exclusions that some employer-sponsored ERISA plans still carry.

The 2022 ASMBS / IFSO joint statement (Eisenberg SOARD 2022;18(12):1345) explicitly superseded the 1991 NIH consensus, lowered BMI thresholds, and disavowed arbitrary preoperative weight-loss requirements as not evidence-based. Most insurers have not yet updated their policies, but the appeal can. A successful bariatric appeal cites ASMBS 2022, IFSO, the relevant pivotal trial (STAMPEDE, SOS, ARMMS-T2D, MERIT, Teen-LABS), and the patient's specific BMI plus comorbidity profile.

The five denial categories you will actually see

Most bariatric denials reduce to five rejections:

1. "BMI does not meet criteria" — the policy may still cite BMI ≥40 or BMI ≥35 + comorbidity. ASMBS 2022 endorses BMI ≥35 alone or BMI ≥30 with metabolic disease. The lower thresholds are the appeal target.

2. "Supervised weight loss program incomplete" — the policy may require 3, 6, or 12 months of monthly visits, dietitian notes, and exercise documentation. ASMBS 2016 explicitly opposed mandated preop weight loss as not evidence-based.

3. "Plan exclusion: bariatric not a covered benefit" — some self-funded ERISA plans still exclude. The appeal mechanism here is different (employer-level).

4. "Investigational" for newer procedures — SADI-S, OAGB, ESG, intragastric balloon, TORe each carry "investigational" labels in many policies despite ASMBS endorsement and FDA clearance.

5. "Revision not justified" — for revision cases, the failure mode (refractory GERD with erosive esophagitis, weight regain with comorbidity recrudescence, mechanical complication) needs explicit documentation.

Each of these has a precise ASMBS, IFSO, AAP, or pivotal-trial counter, and the appeal letter writes itself once the chart is complete.

The BMI threshold debate: ASMBS 2022 changed everything

The 1991 NIH Consensus Statement (Gastrointestinal Surgery for Severe Obesity) set the original thresholds: BMI ≥40, or BMI ≥35 with serious obesity-related comorbidity. Those thresholds persisted in insurer policies for thirty years despite the evidence accumulating that lower-BMI metabolic surgery produces sustained T2DM remission.

The 2022 ASMBS / IFSO joint statement (Eisenberg SOARD 2022) explicitly:

• Endorsed MBS for BMI ≥35 regardless of comorbidity status.
• Endorsed MBS for BMI ≥30 with metabolic disease (T2DM, HbA1c >7%).
• Lowered thresholds for Asian patients to BMI ≥27.5 with metabolic disease and BMI ≥32.5 alone.
• Disavowed arbitrary preoperative weight-loss requirements as not evidence-based.

A successful appeal cites Eisenberg SOARD 2022 by name, the patient's BMI, and the comorbidity profile with explicit measurements:

• HbA1c (>7% if T2DM is present and uncontrolled, or >9% if poorly controlled).
• PSG-confirmed OSA with AHI and CPAP status.
• Hypertension regimen (number of agents, control).
• NAFLD with imaging (FibroScan kPa) or labs (ALT, AST, FibroSure, Fib-4).
• Hyperlipidemia with LDL, TG, statin failure.
• Severe musculoskeletal disability, pseudotumor cerebri, idiopathic intracranial hypertension, severe GERD with erosive esophagitis, infertility from PCOS — all qualifying comorbidities.

The pivotal trials that anchor the BMI argument:

• STAMPEDE (Schauer NEJM 2012, 5-yr 2017) — RYGB and sleeve superior to medical therapy for T2DM in BMI 27–43.
• SOS (Sjöström NEJM 2007 / JAMA 2014 / NEJM 2017) — long-term mortality, T2DM, CV outcomes superior with bariatric surgery.
• ARMMS-T2D (Kirwan Lancet 2024) — pooled long-term T2DM remission across multiple trials.

Cite each by name and journal. The medical director respects literature.

Supervised weight loss programs: the ASMBS 2016 position

Most bariatric denials cite an incomplete supervised weight-loss program. The defense has two parts: produce what was completed, and cite the ASMBS 2016 Position Statement that disavows mandated preop weight loss as a barrier to care.

The successful supervised-program file contains:

• Monthly visits with documented weight at each visit.
• Registered dietitian visits with food diary review and behavior counseling.
• A written exercise plan with adherence documentation.
• Behavioral or psychological support.
• A GLP-1 trial (semaglutide, tirzepatide, liraglutide) with response and tolerability — most insurers now expect this as part of the medical pathway.

If the program is incomplete because the patient lost insurance coverage during the wait, document that. If the patient has progressed comorbidities during the wait, document that. ASMBS 2016 specifically calls out mandated preop weight loss as a barrier that delays definitive therapy and increases morbidity.

Plan exclusions: read the SPD carefully

Some employer-sponsored ERISA plans still exclude bariatric surgery as a benefit category. The first step in any plan-exclusion case is to obtain the Summary Plan Description (SPD) and the certificate of coverage, and read the bariatric language carefully.

Several common patterns:

• The plan excludes "weight loss" surgery but covers treatment of comorbidities (T2DM, OSA, HTN). If MBS is presented as treatment of the comorbidity rather than weight loss per se, some plans will cover.
• The plan covers bariatric surgery only at certain centers of excellence (often MBSAQIP-accredited). Verify that the surgical program is on the approved list.
• The plan excludes bariatric for the member but covers it for dependents, or vice versa. Read carefully.
• The plan was self-funded and the employer can override the standard exclusion through the plan administrator. Engage HR and the employer's benefits team.
• For state-regulated fully-insured plans, some states have laws requiring bariatric coverage for severe obesity (Maryland, Virginia, Indiana, others). Check state law.

Sleeve to RYGB revision: GERD is the central argument

The sleeve gastrectomy is the most common bariatric procedure in the US and worldwide, but 20–30% of sleeve patients develop refractory GERD or weight regain over 5–10 years. The SLEEVEPASS 10-year follow-up (Salminen JAMA 2022) and SM-BOSS 5-year (Peterli JAMA 2018, 5-yr 2021) provide the contemporary durability and complication data.

For sleeve-to-RYGB revision specifically, the defense is GERD severity:

• EGD with Los Angeles grade (LA grade C or D = severe erosive esophagitis).
• DeMeester score from 24-hour pH study or pH-impedance.
• Esophageal manometry to rule out motility disorder.
• Upper GI series showing dilated proximal sleeve, hiatal hernia, or stenotic mid-sleeve.
• PPI dependence with breakthrough symptoms.
• Aspiration symptoms or nocturnal symptoms.

Cite the ASMBS Revisional Bariatric Surgery Position Statement, which supports RYGB conversion for refractory GERD post-sleeve. The technical advantage of RYGB is that the gastric pouch is small and the duodenum is bypassed, eliminating the acid reservoir.

For weight regain after sleeve, the appeal needs to document:

• Weight regain ≥25% of weight lost, or BMI back into qualifying range.
• Comorbidity recrudescence (HbA1c rebound, BP rise, OSA AHI rise).
• The failure mode (sleeve dilation on UGI, dietary noncompliance versus mechanical failure).
• Multidisciplinary team consensus on revision modality (RYGB vs SADI-S vs BPD/DS).

SADI-S and BPD/DS: the malabsorptive arguments

The single-anastomosis duodeno-ileal bypass with sleeve (SADI-S) was endorsed by ASMBS in 2023 (SOARD 2023) as a metabolic surgical option. Many insurer policies still label it experimental. The defense:

• Cite the ASMBS 2023 SADI-S Position Statement by name.
• Cite the IFSO 2018 BPD/DS / SADI-S guidance.
• Cite the foundational SADI-S series (Sánchez-Pernaute SOARD).
• Cite Mingrone NEJM 2012 for BPD outcomes in T2DM.
• Cite Buchwald JAMA 2004 for the meta-analysis of bariatric outcomes.
• For BMI ≥50 (super-obese) and severe T2DM, the malabsorptive procedures produce greater weight loss and T2DM remission than RYGB or sleeve.

For pure BPD/DS, the policy may still cover it under "BPD with duodenal switch." Document the patient anatomy (long-limb vs standard limb) and the surgeon's experience. Programs at MBSAQIP-accredited centers carry weight.

ESG, intragastric balloon, and TORe: FDA-cleared, ASMBS-endorsed

The endoscopic bariatric therapies are routinely denied as "investigational" despite FDA clearance and ASMBS / ASGE endorsement.

For endoscopic sleeve gastroplasty (ESG):

• FDA-cleared via the Apollo OverStitch device.
• The MERIT trial (Abu Dayyeh Lancet 2022) is a multicenter RCT showing ESG superior to lifestyle alone in BMI 30–40.
• Cite the ASMBS / ASGE Position on Endoscopic Bariatric Therapies.
• Document BMI 30–40 with at least one comorbidity, prior weight loss attempts, motivation for endoscopic versus surgical intervention.

For intragastric balloon (Orbera 2015, ReShape 2015, Spatz 2021, Allurion 2023):

• All FDA-approved for BMI 30–40 with comorbidity (specific labels vary).
• ASMBS / ASGE position supports as bridge or selected primary therapy.
• 6-month indwelling time for fluid-filled, longer for swallowable Allurion.
• Document the specific device and FDA indication.

For transoral outlet reduction (TORe) in RYGB weight regain:

• Cite the TWIN trial and the ASMBS Revisional Position.
• Document gastrojejunal anastomosis dilation on endoscopy.
• Distinguish from surgical revision when appropriate (less invasive, lower morbidity).

Adolescent bariatric surgery: AAP 2023 and Teen-LABS

The 2023 AAP Clinical Practice Guideline on the Evaluation and Treatment of Children and Adolescents with Obesity (Hampl Pediatrics 2023) was a major shift — it explicitly endorsed metabolic and bariatric surgery for adolescents with severe obesity and comorbidities, in conjunction with the ASMBS Pediatric Position 2018 / 2023 update.

The thresholds:

• BMI ≥120% of the 95th percentile (Class 2 pediatric obesity) with at least one comorbidity, OR
• BMI ≥140% of the 95th percentile (Class 3 pediatric obesity) regardless of comorbidity.

A successful adolescent bariatric appeal documents:

• Age, sex, height, weight, BMI, BMI percentile, BMI as percentage of 95th percentile.
• Tanner stage (≥4 typically; younger Tanner stages possible in selected severe cases).
• Skeletal maturity on hand X-ray (often skeletally mature at Tanner 4–5).
• Comorbidity profile — T2DM with HbA1c, severe OSA, HTN, NAFLD with fibrosis, idiopathic intracranial hypertension.
• ≥6–12 months of intensive lifestyle therapy at a pediatric MASH (Multi-component Approach to Severe Obesity in Health) program.
• Pediatric multidisciplinary team — pediatric endocrinology, pediatric GI, pediatric psychology, RDN, pediatric bariatric surgeon — all in consensus.
• Teen-LABS 5-year outcomes (Inge JAMA Surg 2019) — sustained weight loss and comorbidity remission.

Cite the AAP 2023 Clinical Practice Guideline (Hampl Pediatrics 2023) and the ASMBS Pediatric Position by name.

Multidisciplinary evaluation and program accreditation

Most insurer policies require performance at a center accredited by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), a joint initiative of the American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS).

A successful bariatric appeal documents:

• The surgical program's MBSAQIP accreditation status (Comprehensive, Adolescent, Bariatric Surgery Center, etc.).
• The multidisciplinary evaluation — surgeon, RDN, psychologist or psychiatrist, medical / endocrine, anesthesia.
• The center's outcomes data when available.
• Surgeon volume and credentialing.

For ESG and intragastric balloon, the proceduralist is often a bariatric endoscopist (gastroenterologist) rather than a bariatric surgeon. Document credentialing and ASGE / ASMBS endorsement of the proceduralist.

The peer-to-peer call: same-specialty matters

Most bariatric denials carry a 14-day peer-to-peer window. Demand a same-specialty reviewer — a bariatric surgeon at an MBSAQIP-accredited program, not a generalist or an internist. Bring three things to the call: the BMI plus comorbidity profile, the supervised program log (or the rationale for waiver per ASMBS 2016), and the ASMBS 2022 Position citation.

The peer-to-peer overturns more bariatric denials than any other appeal mechanism because the medical director is often unfamiliar with the 2022 threshold update and the contemporary endoscopic bariatric therapy landscape.

A note on letter length and structure

A bariatric appeal should be 1.5 to 2 pages. The structure that works:

1. Header with member ID, claim number, procedure, CPT.

2. Diagnosis with ICD-10, BMI explicit, and the comorbidity profile (one paragraph each for T2DM, OSA, HTN, NAFLD, GERD as relevant).

3. Weight history and supervised program documentation.

4. Multidisciplinary evaluation summary.

5. Address the denial directly — quote the insurer's own coverage criteria, demonstrate each is met, cite ASMBS 2022 / IFSO / AAP / pivotal trial.

6. Closing — request overturn within deadline, demand peer-to-peer with same-specialty bariatric surgeon at MBSAQIP-accredited program.

Tone is professional, firm, evidence-driven. Let the BMI, the HbA1c, the AHI, and the ASMBS reference do the work.

When to escalate

Self-funded ERISA plans go through second-level internal appeal then external review under ACA §2719. The employer is also a stakeholder for ERISA exclusion cases — engage HR and the benefits team. Fully-insured state-regulated plans go through state external review, with several states (Maryland, Virginia, Indiana) having explicit bariatric coverage mandates. Medicare Advantage cases route through the Independent Review Entity and the ALJ hearing — note that CMS NCD 100.1 covers RYGB, BPD/DS, sleeve, and lap band at approved facilities. Medicaid follows the state Fair Hearing process. Each level has its own deadlines (typically 60–180 days from the prior denial).

Most bariatric denials reverse on first appeal when ASMBS 2022 is cited, the chart documentation matches the policy criteria, and the peer-to-peer is requested. The work is in the documentation — once the chart contains the right BMI, the right comorbidity workup, and the right ASMBS citation, drafting the letter is mechanical.